Bispecific antibody to ErbB2 overcomes trastuzumab resistance through comprehensive blockade of ErbB2 heterodimerization

Cancer Research

Volumn 73, Issue 21, 2013, Pages 6471-6483

  Li, Bohua ^a,b,c,e   Meng, Yanchun ^a   Zheng, Lei ^a   Zhang, Xunmin ^a   Tong, Qing ^a   Tan, Wenlong ^d   Hu, Shi ^a   Li, Hui ^e   Chen, Yang ^e   Song, Jinjing ^a   Zhang, Ge ^a   Zhao, Lei ^a   Zhang, Dapeng ^a,b,c   Hou, Sheng ^a,b,c,e   Qian, Weizhu ^a,b,c   Guo, Yajun ^a,b,c,d,e  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b National Engineering Research Center for Antibody Medicine   (United States)

^c State Key Laboratory of Antibody Medicine and Targeted Therapy   (United States)

^d SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^e CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BISPECIFIC ANTIBODY; EPIDERMAL GROWTH FACTOR RECEPTOR 2; IMMUNOGLOBULIN G; PERTUZUMAB; TRASTUZUMAB;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIGEN BINDING; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER INHIBITION; CELL PROLIFERATION; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; DIMERIZATION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG RESISTANCE; FEMALE; HETERODIMERIZATION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOPRECIPITATION; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

ANIMALS; ANTIBODIES, BISPECIFIC; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BLOTTING, WESTERN; BREAST NEOPLASMS; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOENZYME TECHNIQUES; IMMUNOPRECIPITATION; MICE; MICE, INBRED BALB C; MICE, NUDE; PROTEIN MULTIMERIZATION; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTOR, ERBB-2; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR CELLS, CULTURED;

EID: 84887198387     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-13-0657     Document Type: Article

References (41)

1. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235: 177-82.
2. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989;244: 707-12.
3. Hudis CA. Trastuzumab-mechanism of action and use in clinical practice. N Engl J Med 2007;357: 39-51.
4. Marty M, Cognetti F, Maraninchi D, Snyder R, Mauriac L, Tubiana-Hulin M, et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol 2005;23: 4265-74.
5. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, et al. Herceptin Adjuvant (HERA) Trial Study Team. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005;353: 1659-72.
6. Romond EH, Perez EA, Bryant J, Suman VJ, GeyerCEJr, Davidson NE, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2- positive breast cancer. N Engl J Med 2005;353: 1673-84.
7. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344: 783-92.
8. Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002;20: 719-26.
9. Nahta R, Esteva FJ. HER2 therapy: molecular mechanisms of trastuzumab resistance. Breast Cancer Res 2006;8: 215.
10. Nahta R, Yu D, Hung MC, Hortobagyi GN, Esteva FJ. Mechanisms of disease: understanding resistance toHER2-targeted therapy in human breast cancer. Nat Clin Pract Oncol 2006;3: 269-80.
11. Ritter CA, Perez-Torres M, Rinehart C, Guix M, Dugger T, Engelman JA, et al.Human breast cancer cells selected for resistance to trastuzumab in vivo overexpress epidermal growth factor receptor and ErbB ligands and remain dependent on the ErbB receptor network. Clin Cancer Res 2007;13: 4909-19.
12. Kumar R. ErbB-dependent signaling as a determinant of trastuzumab resistance. Clin Cancer Res 2007;13: 4657-9.
13. Graus-Porta D, Beerli RR, Daly JM, Hynes NE. ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. EMBO J 1997;16: 1647-55.
14. Hynes NE, Lane HA. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 2005;5: 341-54.
15. Johannessen LE, Haugen KE, østvold AC, Stang E, Madshus IH. Heterodimerization of the epidermal-growth-factor (EGF) receptor and ErbB2 and the affinity of EGF binding are regulated by different mechanisms. Biochem J 2001;356: 87-96.
16. Junttila TT, Akita RW, Parsons K, Fields C, Lewis Phillips GD, Friedman LS, et al. Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941. Cancer Cell 2009;15: 429-40.
17. Kumagai T, Katsumata M, Hasegawa A, Furuuchi K, Funakoshi T, Kawase I, et al. Role of extracellular subdomains of p185c-neu and the epidermal growth factor receptor in ligand-independent association and transactivation. Proc Natl Acad Sci U S A 2003; 100: 9220-5.
18. Spector NL, Blackwell KL. Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2- positive breast cancer. J Clin Oncol 2009;27: 5838-47.
19. Wehrman TS, Raab WJ, Casipit CL, Doyonnas R, Pomerantz JH, Blau HM. A system for quantifying dynamic protein interactions defines a role for Herceptin in modulating ErbB2 interactions. Proc Natl Acad Sci U S A 2006;103: 19063-8.
20. Agus DB, Akita RW, Fox WD, Lewis GD, Higgins B, Pisacane PI, et al. Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. Cancer Cell 2002;2: 127-37.
21. Adams CW, Allison DE, Flagella K, Presta L, Clarke J, Dybdal N, et al. Humanization of a recombinant monoclonal antibody to produce a therapeutic HER dimerization inhibitor, pertuzumab. Cancer Immunol Immunother 2006;55: 717-27.
22. Cho HS, Mason K, Ramyar KX, Stanley AM, Gabelli SB, DenneyDWJr, et al. Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature 2003;421: 756-60.
23. Franklin MC, Carey KD, Vajdos FF, Leahy DJ, de Vos AM, Sliwkowski MX. Insights into ErbB signaling from the structure of the ErbB2- pertuzumab complex. Cancer Cell 2004;5: 317-28.
24. Nahta R, Hung MC, Esteva FJ. The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells. Cancer Res 2004;64: 2343-6.
25. Scheuer W, Friess T, Burtscher H, Bossenmaier B, Endl J, Hasmann M. Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models. Cancer Res 2009;69: 9330-6.
26. Baselga J, Gelmon KA, Verma S, Wardley A, Conte P, Miles D, et al. Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy. J Clin Oncol 2010;28: 1138-44.
27. Cortes J, Fumoleau P, Bianchi GV, Petrella TM, Gelmon K, Pivot X, et al. Pertuzumab monotherapy after trastuzumab-based treatment and subsequent reintroduction of trastuzumab: activity and tolerability in patients with advanced human epidermal growth factor receptor 2- positive breast cancer. J Clin Oncol 2012;30: 1594-600.
28. Li B, Shi S, Qian W, Zhao L, Zhang D, HouS, et al. Development of novel tetravalent anti-CD20 antibodies with potent antitumor activity. Cancer Res 2008;68: 2400-8.
29. Li B, Zhao L, Guo H, Wang C, Zhang X,WuL, et al. Characterization of a rituximab variant with potent antitumor activity against rituximabresistant B-cell lymphoma. Blood 2009;114: 5007-15.
30. Wu C, Ying H, Grinnell C, Bryant S, Miller R, Clabbers A, et al. Simultaneous targeting of multiple disease mediators by a dual-variable- domain immunoglobulin. Nat Biotechnol 2007;25: 1290-7.
31. Carter P, Presta L, Gorman CM, Ridgway JB, Henner D, Wong WL, et al. Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci USA 1992;89: 4285-9.
32. Li B, Zhao L, Wang C, Guo H, Wu L, Zhang X, et al. The protein-protein interface evolution acts in a similar way to antibody affinity maturation. J Biol Chem 2010;285: 3865-71.
33. Du J, Wang H, Zhong C, Peng B, Zhang M, Li B, et al. Crystal structure of chimeric antibody C2H7 Fab in complex with a CD20 peptide. Mol Immunol 2008;45: 2861-8.
34. Lu D, Kotanides H, Jimenez X, Zhou Q, Persaud K, Bohlen P, et al. Acquired antagonistic activity of a bispecific diabody directed against two different epitopes on vascular endothelial growth factor receptor 2. J Immunol Methods 1999;230: 159-71.
35. Roskoski R Jr. VEGF receptor protein-tyrosine kinases: structure and regulation. Biochem Biophys Res Commun 2008;375: 287-91.
36. Blackwell KL, Burstein HJ, Storniolo AM, Rugo H, Sledge G, Koehler M, et al. Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J Clin Oncol 2010;28: 1124-30.
37. von Minckwitz G, du Bois A, Schmidt M, Maass N, Cufer T, de Jongh FE, et al. Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study. J Clin Oncol 2009;27: 1999-2006.
38. Krop I. Doubling down on human epidermal growth factor receptor 2. J Clin Oncol 2012;30: 1574-6.
39. Barginear MF, John V, Budman DR. Trastuzumab-DM1: a clinical update of the novel antibody-drug conjugate for HER2-overexpressing breast cancer. Mol Med 2013;18: 1473-9.
40. Girish S, Gupta M, Wang B, Lu D, Krop IE, Vogel CL, et al. Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody-drug conjugate in development for the treatment of HER2-positive cancer. Cancer Chemother Pharmacol 2012;69: 1229-40.
41. Krop IE, LoRusso P, Miller KD, Modi S, Yardley D, Rodriguez G, et al. A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine. J Clin Oncol 2012;30: 3234-41.